Literature DB >> 19171054

New discoveries on the biology and detection of human chorionic gonadotropin.

Laurence A Cole1.   

Abstract

Human chorionic gonadotropin (hCG) is a glycoprotein hormone comprising 2 subunits, alpha and beta joined non covalently. While similar in structure to luteinizing hormone (LH), hCG exists in multiple hormonal and non-endocrine agents, rather than as a single molecule like LH and the other glycoprotein hormones. These are regular hCG, hyperglycosylated hCG and the free beta-subunit of hyperglycosylated hCG. For 88 years regular hCG has been known as a promoter of corpus luteal progesterone production, even though this function only explains 3 weeks of a full gestations production of regular hCG. Research in recent years has explained the full gestational production by demonstration of critical functions in trophoblast differentiation and in fetal nutrition through myometrial spiral artery angiogenesis. While regular hCG is made by fused villous syncytiotrophoblast cells, extravillous invasive cytotrophoblast cells make the variant hyperglycosylated hCG. This variant is an autocrine factor, acting on extravillous invasive cytotrophoblast cells to initiate and control invasion as occurs at implantation of pregnancy and the establishment of hemochorial placentation, and malignancy as occurs in invasive hydatidiform mole and choriocarcinoma. Hyperglycosylated hCG inhibits apoptosis in extravillous invasive cytotrophoblast cells promoting cell invasion, growth and malignancy. Other non-trophoblastic malignancies retro-differentiate and produce a hyperglycosylated free beta-subunit of hCG (hCG free beta). This has been shown to be an autocrine factor antagonizing apoptosis furthering cancer cell growth and malignancy. New applications have been demonstrated for total hCG measurements and detection of the 3 hCG variants in pregnancy detection, monitoring pregnancy outcome, determining risk for Down syndrome fetus, predicting preeclampsia, detecting pituitary hCG, detecting and managing gestational trophoblastic diseases, diagnosing quiescent gestational trophoblastic disease, diagnosing placental site trophoblastic tumor, managing testicular germ cell malignancies, and monitoring other human malignancies. There are very few molecules with such wide and varying functions as regular hCG and its variants, and very few tests with such a wide spectrum of clinical applications as total hCG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171054      PMCID: PMC2649930          DOI: 10.1186/1477-7827-7-8

Source DB:  PubMed          Journal:  Reprod Biol Endocrinol        ISSN: 1477-7827            Impact factor:   5.211


  234 in total

1.  Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices.

Authors:  S A Butler; S A Khanlian; L A Cole
Journal:  Clin Chem       Date:  2001-12       Impact factor: 8.327

Review 2.  Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia.

Authors:  Peter Kaufmann; Simon Black; Berthold Huppertz
Journal:  Biol Reprod       Date:  2003-03-05       Impact factor: 4.285

3.  Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass.

Authors:  L A Cole; J H Nam; J T Chambers; P E Schwartz
Journal:  Gynecol Oncol       Date:  1990-03       Impact factor: 5.482

4.  Isolation and characterization of human pituitary chorionic gonadotropin.

Authors:  S Birken; Y Maydelman; M A Gawinowicz; A Pound; Y Liu; A S Hartree
Journal:  Endocrinology       Date:  1996-04       Impact factor: 4.736

5.  Different asparagine-linked sugar chains on the two polypeptide chains of human chorionic gonadotropin.

Authors:  T Mizuochi; A Kobata
Journal:  Biochem Biophys Res Commun       Date:  1980-11-28       Impact factor: 3.575

6.  Phantom hCG and phantom choriocarcinoma.

Authors:  L A Cole
Journal:  Gynecol Oncol       Date:  1998-11       Impact factor: 5.482

7.  Have we found the "definitive cancer biomarker"? The diagnostic and therapeutic implications of human chorionic gonadotropin-beta expression as a key to malignancy.

Authors:  W Regelson
Journal:  Cancer       Date:  1995-10-15       Impact factor: 6.860

8.  Regulation of trophoblast invasion by IL-1beta and TGF-beta1.

Authors:  Subhradip Karmakar; Chandana Das
Journal:  Am J Reprod Immunol       Date:  2002-10       Impact factor: 3.886

9.  Effect of desialylation of human chorionic gonadotropin on its metabolic clearance rate in humans.

Authors:  C Rosa; S Amr; S Birken; R Wehmann; B Nisula
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

10.  Use of serum FSH to identify perimenopausal women with pituitary hCG.

Authors:  Ann M Gronowski; Corinne R Fantz; Curtis A Parvin; Lori J Sokoll; Carmen L Wiley; Mark H Wener; David G Grenache
Journal:  Clin Chem       Date:  2008-02-07       Impact factor: 8.327

View more
  58 in total

Review 1.  The hydatidiform mole.

Authors:  Jean-Jacques Candelier
Journal:  Cell Adh Migr       Date:  2015-09-30       Impact factor: 3.405

2.  Unbalanced human embryos secrete more hyperglycosylated human chorionic gonadotrophin (hCG-H) than balanced ones.

Authors:  Dimitar Parvanov; Dragomira Nikolova; Rumiana Ganeva; Kristina Nikolova; Magdalena Vasileva; Ivaylo Rangelov; Maria Pancheva; Maria Serafimova; Rada Staneva; Savina Hadjidekova; Fabio Scarpellini; Georgi Stamenov
Journal:  J Assist Reprod Genet       Date:  2020-04-22       Impact factor: 3.412

3.  HEMO, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors.

Authors:  Odile Heidmann; Anthony Béguin; Janio Paternina; Raphaël Berthier; Marc Deloger; Olivia Bawa; Thierry Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

4.  Does the degree of endocrine dyscrasia post-reproduction dictate post-reproductive lifespan? Lessons from semelparous and iteroparous species.

Authors:  Craig S Atwood; Kentaro Hayashi; Sivan Vadakkadath Meethal; Tina Gonzales; Richard L Bowen
Journal:  Geroscience       Date:  2017-03-07       Impact factor: 7.713

5.  Pro-angiogenic effects of pregnancy-specific glycoproteins in endothelial and extravillous trophoblast cells.

Authors:  Shemona Rattila; Florian Kleefeldt; Angela Ballesteros; Jimena S Beltrame; Maria L Ribeiro; Süleyman Ergün; Gabriela Dveksler
Journal:  Reproduction       Date:  2020-11       Impact factor: 3.906

Review 6.  Reproductive tract function and dysfunction in women.

Authors:  Angshumoy Roy; Martin M Matzuk
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

7.  Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.

Authors:  D Carone; C Caropreso; A Vitti; R Chiappetta
Journal:  J Endocrinol Invest       Date:  2012-10-22       Impact factor: 4.256

8.  Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer.

Authors:  Adetunji T Toriola; Egle Tolockiene; Helena Schock; Helja-Marja Surcel; Anne Zeleniuch-Jacquotte; Goran Wadell; Paolo Toniolo; Eva Lundin; Kjell Grankvist; Annekatrin Lukanova
Journal:  Future Oncol       Date:  2014-02       Impact factor: 3.404

9.  The pregnancy hormones human chorionic gonadotropin and progesterone induce human embryonic stem cell proliferation and differentiation into neuroectodermal rosettes.

Authors:  Miguel J Gallego; Prashob Porayette; Maria M Kaltcheva; Richard L Bowen; Sivan Vadakkadath Meethal; Craig S Atwood
Journal:  Stem Cell Res Ther       Date:  2010-09-13       Impact factor: 6.832

10.  Pleomorphic carcinoma of the lung with high serum beta-human chorionic gonadotropin level and gynecomastia.

Authors:  Kerem Okutur; Baris Hasbal; Kubra Aydin; Mustafa Bozkurt; Esat Namal; Buge Oz; Kamil Kaynak; Gokhan Demir
Journal:  J Korean Med Sci       Date:  2010-11-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.